It looks at the rise of fraudulent research and scientists in the life sciences industry, the reasons for the rise, and suggests some measures that companies can take to counter this growing threat to the reputation of the industry and to the safety and security of healthcare delivery.
This silent crisis has dire consequences. Patients face delays, errors increase and the entire system suffers. This cannot continue. But in the face of such crippling challenges, how can healthcare practices look to improve the interoperability of their systems?
Angioplasty and stenting procedures (or percutaneous coronary interventions/PCIs) are performed more than four million times around the world every year to open up blockages in coronary arteries to allow the heart to receive proper blood flow. Most of these procedures — 80-85 percent — are only guided by traditional angiography, an x-ray of the blood vessels that requires a contrast agent to be flushed into the heart to identify where the blockages are.
As healthcare pushes forward in digital transformation, AI has emerged as a critical tool in optimizing electronic medical records. EMRs remain both vital and frustrating. Clinicians wrestle with usability, while patients struggle with engagement and access. By integrating AI thoughtfully and securely, we can create a more intuitive, efficient and user-centric experience for both groups.
MTI Viewpoint: I expect fundamental changes to our medical device ecosystem; not all companies will survive them. The ability to consistently use AI will also determine who will be among the survivors and even the winners. AI will not only be part of the devices but also an internal tool.
AI’s reach depends on the environments in which it operates as well as how it is developed and deployed, highlighting a fundamental debate on whether we should push for regulation or opt for free-market-driven deregulation.
With a new executive order to leave the World Health Organization, the Make America Healthy Again (MAHA) movement is driving new policy and promises for faster time to market for product innovation. MedTech start-ups are keen to capitalize on the opportunity, yet funding to push product through early product phases – concept and design through clinical studies and post-market surveillance – can be complex. Daniele Viappiani of GC1 Ventures offers strategies for MedTech start-ups to find the right investors.
Leveraging awareness communications to grasp the potential opportunity for medical devices designed to monitor health and chronic illnesses offered by the new US administration.
What’s getting R&D attention? The impact of upcoming regulations, A.I., new cybersecurity risks, developments in battery power and innovation, collaborative efforts, and other impacts on the industry in the year ahead.
Wearables such as smart watches or sensor rings are already a routine part of everyday life and are also popular Christmas gifts. They track our pulse rate, count our steps or analyze our sleep patterns. How can they already influence our behavior today and what future developments are possible?
